Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas

Inclusion Criteria:

Eligibility will be determined separately for Part I and Part II of this study:

Part I ( Part I Eligibility criteria (eligibility for undergoing apheresis procedure)

* Age ≤ 25 years at initial diagnosis.
* Must have one of the following diagnoses:
* High risk neuroblastoma
* Metastatic or recurrent retinoblastoma
* High risk rain tumors
* Recurrent or refractory Hodgkin disease
* Recurrent or advanced stage Wilms tumor
* Recurrent or metastatic sarcomas
* Recurrent or refractory non-Hodgkin lymphoma
* Desmoplastic small round cell tumor.
* Lansky or Karnofsky Performance Score ≥ 70.
* Creatinine ≤ 2.0 mg/dl.
* Direct bilirubin ≤ 2.0 mg/dl.
* SGPT ≤ 2 x upper limit of normal
* HIV testing
* Negative pregnancy test
* Patients with significant prior radiation therapy to the liver will be excluded.

Part II eligibility criteria (criteria for transplantation of CD133 select stem cell product)

* Successfully completed Part I of protocol treatment plan and has the following available:
* Stored autologous bone marrow or peripheral blood stem cells (i.e. 2 x 106 unselected CD34+ cells/ kg PBSC or 1 x 106 CD34+ cells/ kg BM) for back up.
* Stored autologous bone marrow or peripheral blood stem cells (2 x 106 CD133+ cells/ kg PBSC or 2 x 106 CD133+ cells/ kg BM) for infusion.
* Forced vital capacity greater than or equal to 40% normal or pulse oximetry greater than or equal to 92% on room air.
* Lansky or Karnofsky Performance Score ≥ 70.
* Creatinine ≤ 2.0 mg/dl.
* Direct bilirubin ≤ 2.0 mg/dl.
* SGPT ≤ 2 x upper limit of normal
* Negative pregnancy test
* Patients with significant prior radiation therapy (in opinion of the PI) to the liver will be excluded.